Monimus Capital Management LP Purchases Shares of 263,644 2seventy bio, Inc. (NASDAQ:TSVT)

Monimus Capital Management LP purchased a new stake in 2seventy bio, Inc. (NASDAQ:TSVT) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 263,644 shares of the company’s stock, valued at approximately $775,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Erste Asset Management GmbH acquired a new position in shares of 2seventy bio during the 3rd quarter worth approximately $25,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of 2seventy bio during the 4th quarter worth approximately $32,000. Readystate Asset Management LP acquired a new position in shares of 2seventy bio during the 3rd quarter worth approximately $53,000. GSA Capital Partners LLP acquired a new stake in shares of 2seventy bio during the 3rd quarter worth approximately $64,000. Finally, Intech Investment Management LLC acquired a new stake in shares of 2seventy bio during the 3rd quarter worth approximately $69,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

Insider Transactions at 2seventy bio

In other 2seventy bio news, major shareholder Global Healthcare Master Kynam sold 5,142,111 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $4.93, for a total value of $25,350,607.23. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

TSVT has been the topic of several analyst reports. Morgan Stanley reduced their price target on shares of 2seventy bio from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Friday. Leerink Partners reiterated a “market perform” rating and set a $5.00 price target (down previously from $9.00) on shares of 2seventy bio in a research report on Tuesday. Leerink Partnrs lowered shares of 2seventy bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of 2seventy bio in a research report on Friday, March 7th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $6.67.

2seventy bio Price Performance

NASDAQ:TSVT opened at $4.95 on Friday. The firm has a 50-day moving average of $2.72 and a 200-day moving average of $3.70. The company has a market cap of $255.36 million, a PE ratio of -2.66 and a beta of 1.73. 2seventy bio, Inc. has a one year low of $2.29 and a one year high of $5.99.

2seventy bio Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.